Nuclear receptors as therapeutic targets for Alzheimer's disease - Test2 - elhamkhani - TriplyDB

Nuclear receptors as therapeutic targets for Alzheimer's disease

Nuclear receptors as therapeutic targets for Alzheimer's disease

http://www.wikidata.org/entity/Q35165186

about

Impact of apolipoprotein E on Alzheimer's disease ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models PPAR-γ -- a possible drug target for complicated pregnancies Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction Mitochondrial dysfunction in neurodegenerative diseases Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease Nuclear receptors in neurodegenerative diseases.Insulin resistance in Alzheimer's disease.Effects of NR1H3 genetic variation on the expression of liver X receptor α and the progression of Alzheimer's disease Microglia: scapegoat, saboteur, or something else?Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.Daidzein Augments Cholesterol Homeostasis via ApoE to Promote Functional Recovery in Chronic Stroke Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"Lentiviral-Mediated Overexpression of the 18 kDa Translocator Protein (TSPO) in the Hippocampal Dentate Gyrus Ameliorates LPS-Induced Cognitive Impairment in Mice.Transcriptional regulation and its misregulation in Alzheimer's disease.Long-term caloric restriction in ApoE-deficient mice results in neuroprotection via Fgf21-induced AMPK/mTOR pathway.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.PPARγ recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation The neuroendocrine control of the innate immune system in health and brain diseases.Receptor-based targeting of therapeutics.Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier.Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Anti-neuroinflammatory agents for the treatment of Alzheimer's disease.Hypercholesterolaemia-induced oxidative stress at the blood-brain barrier.The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence.Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.Regulation of behaviour by the nuclear receptor TLX.Development of Cerebral Microbleeds in the APP23-Transgenic Mouse Model of Cerebral Amyloid Angiopathy-A 9.4 Tesla MRI Study.NR4A nuclear receptors support memory enhancement by histone deacetylase inhibitors.A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects Targeting Neuroinflammation to Treat Alzheimer's Disease.PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARγ.

P2860

Q24567759-BFAB2700-B518-4057-A149-84CAD7667E6B Q24628845-04D8E14D-74EC-40D8-9E6B-9F9468D9838D Q26863678-01F20BEC-1804-47C7-81DA-6A705853450A Q28273620-5648D086-0A84-4589-A38B-6CEF4E032523 Q28283718-767F50E2-5CE0-4041-8438-F8221DDB591D Q28387647-01FF1D48-D6D9-426D-A6C8-20C969ED0ECA Q28535014-F9D8B14F-C18C-4FB6-9AAD-D711BB90DAD0 Q33562308-B4FA8883-8150-4D20-B82A-717DF322E3A7 Q34580020-C3E8755C-0FA2-4A08-88FA-85108CF8F4F2 Q34622157-5476FDDF-F635-4D54-9E46-12247E665869 Q35053654-71CEA289-E414-4304-AFD9-28EB05D115EE Q35606301-A81A9067-B203-4D20-9189-B5BF1FECEC21 Q36208400-F41E64EE-E5A6-4FAD-BA6A-4E92033236FC Q36272544-8E978919-36F0-4CE2-9463-7C2761E13E75 Q36771721-40943C9C-A111-407F-AC8C-E11A47331FBC Q37022972-804E1E66-3D2C-4487-8448-E70E2C96BF16 Q37346461-4F05889B-B685-4642-9FA6-2B22C2E49A6C Q37370537-1D3EBECE-E476-4939-8736-E1C9291D8EC5 Q37538200-06E29065-AE29-4E0B-8BA8-C6502A3E1318 Q37559812-A549ADC0-E6BF-49E2-9AE6-4DD578D16342 Q37633627-A7238D70-5C50-4B79-9701-3320213BBCA5 Q37728905-A56B8850-9875-4DAB-A468-9C51E78D7A38 Q38020956-937B6E2E-57C9-45C8-82BF-750559A3E7BD Q38084739-DB4E57A8-B8CA-4410-BDC9-49DFE19998E5 Q38089668-4C1EDAE9-DAA0-4610-B3E6-3E1647551FBD Q38108433-10F050BC-B437-4B3D-9B40-498677376C2F Q38127470-A8C84EEA-F97E-4D7D-B6B2-9FB7BD5A5C98 Q38136313-2D411596-755B-4190-99CB-266263BE1D63 Q38238644-0EC6C1DF-E17E-4AA4-89A9-06D7472C897D Q38364682-12C9F5C0-860F-4460-92E4-7342F1E65368 Q38569669-5CB22CB6-D94F-4FA5-BD4A-7CCA27F84E58 Q38733357-9DA8F8C1-7EAC-4526-B742-A5B0608945C9 Q38993454-EDB2902A-140B-426B-AFE4-19E11FE9A263 Q42095705-2C25F6A6-4D4D-4D44-91FF-A7DC10D70878 Q42536118-46401703-4D83-4AFA-A78D-81D75921FE18 Q42689665-1859D7B2-DAAA-4F92-9234-33210E4C8270 Q47188911-25C9ADD3-EFBF-4A40-BE4C-0BE63BB60EE6 Q47322495-EFE2DB15-BE45-42EE-9F40-B55857EC6989 Q47570646-7AB9955E-F136-4F1B-A082-9AE1EB4215A6 Q48372341-5BBC484B-EEB2-48BA-89C4-7F02AD058125

P2860

Nuclear receptors as therapeutic targets for Alzheimer's disease

http://www.wikidata.org/entity/Q35165186

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Nuclear receptors as therapeutic targets for Alzheimer's disease

@ast

Nuclear receptors as therapeutic targets for Alzheimer's disease

@en

type

label

Nuclear receptors as therapeutic targets for Alzheimer's disease

@ast

Nuclear receptors as therapeutic targets for Alzheimer's disease

@en

prefLabel

Nuclear receptors as therapeutic targets for Alzheimer's disease

@ast

Nuclear receptors as therapeutic targets for Alzheimer's disease

@en

P1433

Q35165186-1D663457-DB7C-42B2-9A1A-5F9F40EB4FB0

P1476

Q35165186-6279F791-20FD-4849-9BF2-468D72B9BD4C

P2093

Q35165186-AC2ED509-7F77-47EA-82DE-D98841899696

Q35165186-F7CD7961-D7F6-4605-BC33-6DC8305FEA69

P2860

Q35165186-04313022-CB14-49F5-A9BF-1FBD72DC60A5

Q35165186-0511B030-CD35-4CF3-8B23-82657DC81AD4

Q35165186-061B80FA-E09A-43D4-AF12-B76642FE57DD

Q35165186-06BA6FBC-FA02-4F97-BF70-8C9B5D8A9796

Q35165186-08896886-3C2C-40BD-9ECC-3768ACF20C8C

Q35165186-0ACF0A84-7295-4477-9AD2-7949A23E6726

Q35165186-0AE427C6-EC19-4285-B1AE-B20C62B361D6

Q35165186-0DC5281C-6168-4444-B34E-739C8B0319C5

Q35165186-0F1B731E-5B71-42A9-A58C-2B96051DF752

Q35165186-0FB216F8-8B97-439D-A761-9478E6E9850F

P304

Q35165186-71A4FEAD-6459-46BD-B4FE-5A56C20C585B

P31

Q35165186-FF915D6E-9BDB-488A-9898-64B8D502AD1A

P356

Q35165186-15EF0085-0F15-4D6C-8BE3-1956C784CED1

P407

Q35165186-9CE3CF9B-D7AB-43C3-8AB5-7A18D2F825D7

P433

Q35165186-50C0F444-91E5-479E-889A-349674B4CE84

P478

Q35165186-F06E57AC-5132-49B1-9395-0C322F3EC0BC

P577

Q35165186-D7318581-1AF5-4759-8C55-C79DB014195C

P5875

Q35165186-00681CE9-C608-4982-ADCD-5551A4EB73C2

P698

Q35165186-EC229BD4-48DF-43A5-9BB2-381B22127839

P921

Q35165186-4404BE4F-9285-44D6-95B0-BA52D64A441E

P932

Q35165186-7271ABEC-9D64-4EFB-B6C8-A4FE65084732

P356

14728222.2011.594043

P1433

Expert Opinion on Therapeutic Targets

P1476

Nuclear receptors as therapeutic targets for Alzheimer's disease

@en

P2093

Gary E Landreth

http://www.w3.org/2001/XMLSchema#string

Shweta Mandrekar-Colucci

http://www.w3.org/2001/XMLSchema#string

P2860

A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway

Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration

PPAR delta: a dagger in the heart of the metabolic syndrome.

Binding of type II nuclear receptors and estrogen receptor to full and half-site estrogen response elements in vitro

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study

PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance

ApoE promotes the proteolytic degradation of Abeta

P304

1085-1097

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2011.594043

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51456718

http://www.w3.org/2001/XMLSchema#string

P698

21718217

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3156324

http://www.w3.org/2001/XMLSchema#string